Genitourinary Cancers | Tumor

You Can’t Spell Patient Without AI

October 8th 2024, 5:00pm

Article

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a helpful tool.

Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC

October 4th 2024, 9:00pm

Article

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney Cancer

October 1st 2024, 1:00pm

Article

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Prostate Cancer Questions Answered on Surgery, Side Effects and More

September 27th 2024, 7:00pm

Article

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

Supplemental New Drug Application Submitted for Nubeqa in Prostate Cancer Subset

September 27th 2024, 1:00pm

Article

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Kidney Cancer Questions Answered, From Protein Intake to Clinical Trials

September 26th 2024, 3:00pm

Article

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Kidney Cancer FAQs Answered on Treatments, Care Teams and More

September 24th 2024, 7:00pm

Article

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

Nubeqa Plus ADT Outperformed ADT Alone in Treating Prostate Cancer

September 23rd 2024, 9:00pm

Article

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Challenges to Consider While Receiving Fotivda for Kidney Cancer

September 21st 2024, 2:00pm

Video

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma

September 20th 2024, 7:00pm

Article

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.